


Stabilis



Oxacillin sodium



Noms commerciaux

Bactocill	Etats Unis d'Amérique
Bioxalin	Pérou
Bristopen	Maroc
Istopen	France
Lioxac	Pérou
Oxacil	Tunisie
Oxacilil	Brésil
Oxacilina	Brésil, Colombie, Equateur, Pérou, Roumanie, Vénézuéla
Oxacillin	Etats Unis d'Amérique
Oxacip	Vénézuéla
Oxalin	Pérou
Oxamicin	Vénézuéla
Oxanon	Brésil
Oxipen	Vénézuéla
Pebenal	Vénézuéla
Staphymicine	Maroc



Stabilité des solutions

PVC		120 mg/ml	25°C	?	3			13
PVC		120 mg/ml	5°C		14			13
PVC		20 mg/ml	-20°C		30			576
EVA		10 mg/ml	23°C		7			1705
EVA		10 mg/ml	4°C		30			1705
PI		10 & 80 mg/ml	25°C	?	24			604
PI		10 & 80 mg/ml	4°C		10			604
?		10 & 100 mg/ml	25°C	?	4			3589
?		10 & 100 mg/ml	4°C	?	7			3589
?		166 mg/ml	-15°C		30			3589
?		50 & 100 mg/ml	-15°C		30			3589

?	▲	10 & 100 mg/ml	25°C	?	4	☾		3589
?	▲	10 & 100 mg/ml	4°C	?	7	☾		3589
?	▲	100 mg/ml	-15°C	☀	30	☾		3589
?	◆	0,5 & 2 mg/ml	25°C	?	6	☑		3589
?	◆	10 & 100 mg/ml	-15°C	☀	30	☾		3589
?	◆	10 & 30 mg/ml	4°C	?	4	☾		3589
?	RL	0,5 & 2 mg/ml	25°C	?	6	☑		3589
?	RL	10 & 100 mg/ml	-15°C	☀	30	☾		3589
?	RL	10 & 30 mg/ml	4°C	?	4	☾		3589



Stabilité en mélange

?	☾	[]	- +	☀	🧬		🕒	📖
?	◆	2 mg/ml	23°C-25°C	☀	Dopamine hydrochloride : 0,8 mg/ml	24	☑	738



Facteur influençant la stabilité













☾	🌾	➡	🧬	999
☾	NaH CO ₃	➡	🧬	150
- +	⬆	➡	📊	3227



Compatibilités

		🧬	☾	📖
☑	Oxacillin sodium : 20 mg/ml Aciclovir sodium : 5 mg/ml		◆	336
🧬	☒ Oxacillin sodium Amikacin sulfate			3549
☒	☒ Oxacillin sodium Ciprofloxacine lactate			3529
☑	Oxacillin sodium : 100 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		▲	198
☒	☒ Oxacillin sodium Dopamine hydrochloride			3638
☒	☒ Oxacillin sodium : 250 mg/ml		NaH CO ₃	150
☒	☒ Oxacillin sodium Cytarabine			3580

	Oxacillin sodium : 10 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
	Oxacillin sodium : 2 mg/ml Dopamine hydrochloride : 0.8 mg/ml		738
	Oxacillin sodium Erythromycin lactobionate		3674
	Oxacillin sodium : 167 mg/ml		999
	Oxacillin sodium : 20 mg/ml Doxapram hydrochloride : 2 mg/ml		1802
	Oxacillin sodium : 20 mg/ml Famotidine		397
	Oxacillin sodium : 40 mg/ml Fluconazole : 2 mg/ml		496
	Oxacillin sodium : 40 mg/ml Foscarnet sodium : 24 mg/ml		73
	Oxacillin sodium : 20 mg/ml Foscarnet sodium : 24 mg/ml		1135
	Oxacillin sodium Gentamicin sulfate		3643
	Oxacillin sodium Gentamicin sulfate		3520
	Oxacillin sodium : 100 mg/ml Heparin sodium : 1 UI/ml		1228
	Oxacillin sodium : 100 mg/ml Heparin sodium : 1 UI/ml	RL	1228
	Oxacillin sodium : 100 mg/ml Hydrocortisone sodium succinate : 1 mg/ml	RL	1228
	Oxacillin sodium : 100 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		1228
	Oxacillin sodium : 20 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
	Oxacillin sodium : 10 mg/ml Labetalol hydrochloride : 1 mg/ml		386
	Oxacillin sodium : 167 mg/ml Levofloxacin : 5 mg/ml		1072
	Oxacillin sodium : 20 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml		1047
	Oxacillin sodium : 250 mg/ml Methotrexate sodium : 30 mg/ml		150
	Oxacillin sodium : 20 mg/ml Morphine sulfate : 1 mg/ml		405
	Oxacillin sodium : 20 mg/ml Pethidine hydrochloride : 10 mg/ml		405
	Oxacillin sodium : 100 mg/ml Potassium chloride : 40 mEq/l	RL	1228
	Oxacillin sodium : 100 mg/ml Potassium chloride : 40 mEq/l		1228
	Oxacillin sodium : 250 mg/ml Sodium bicarbonate : 14 mg/ml		150
	Oxacillin sodium : 40 mg/ml Tacrolimus : 1000 µg/ml		479

		Oxacillin sodium : 20 mg/ml Vancomycin hydrochloride : 10 mg/ml		3813
		Oxacillin sodium : 4 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Oxacillin sodium : 40 mg/ml Verapamil hydrochloride : 2.5 mg/ml		371
		Oxacillin sodium : 20 mg/ml Zidovudine : 4 mg/ml		337
		Oxacillin sodium : 250 mg/ml		150



Voie d'administration



Bibliographie













































	Type	Source
13	Revue	Stiles ML, Allen LV. Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium and tobramycin sulfate in polyvinyl chloride drug reservoirs. Am J Health-Syst Pharm 1997 ; 54: 1068-1070.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
150	Revue	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
371	Revue	Thompson DF, Stiles ML, Allen LV, Tu YH. Compatibility of verapamil hydrochloride with penicillin admixtures during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 142-145.
386	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
397	Revue	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.

405	Revue	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
576	Revue	Holmes CJ, Ausman RK, Walter CW, Kundsins RB. Activity of antibiotic admixtures subjected to different freeze-thaw treatments. Drug Intell Clin Pharm 1980 ; 14: 353-357.
604	Laboratoire	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
738	Revue	Gardella LA, Kesler H, Amann A, Carter JE. Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives. Am J Hosp Pharm 1978 ; 35: 581-584.
999	Revue	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1047	Revue	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072	Revue	Saltzman CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1135	Revue	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1228	Revue	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1705	Revue	Zhang Y, Trissel LA. Stability of ampicillin sodium, nafcillin sodium, and oxacillin sodium in autodose system bags. Int J Pharm Compound 2002 ; 6: 226-229.
1802	Revue	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
3227	Revue	Simon B, Hancu G, Gy?resi A. Application of capillary electrophoresis to the simultaneous determination and stability study of four extensively used penicillin derivatives Braz J Pharm Sci 2014 ; 50, 3 : 521-527.
3520	Laboratoire	Cidomycin - Summary of product Characteristics. Sanofi 2011
3529	Laboratoire	Ciprofloxacin – Summary of Product Characteristics Hospira 2013
3549	Laboratoire	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012

3580	Laboratoire	Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016
3589	Laboratoire	Oxacilline PanPharma – Résumé des caractéristiques du produits PanPharma 2013
3638	Laboratoire	Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics Hospira 2010
3643	Laboratoire	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3813	Revue	Teibel H.M, Knoderer C.A, Nichols K.R. Compatibility of Vancomycin and Oxacillin During Simulated Y-Site Delivery. Hosp Pharm 2015 ; 50, 8: 710-713.



Dictionnaire

 Antibiotique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Polyvinyl chlorure
 Eau pour préparation injectable	 Non précisée
 Jour	 A l'abri de la lumière
 Glucose 5%	 Ethylène vinyl acétate
 Chlorure de sodium 0,9%	 Elastomère en polyisoprène
 NaCl 0,9% ou glucose 5%	 Heure
 Non précisé	RL Ringer lactate
 Stabilité en mélange	 Solvant
 Molécule	 Verre
 Lumière	 Facteur influençant la stabilité
 Nutrition parentérale (mélange binaire)	 Provoque
 Dégradation	 NaHCO ₃
 Augmentation	 Diminution de la stabilité
 Compatibilités	 Compatible
 Instabilité chimique	 Incompatible
 Incompatibilité non précisée	 Dégagement gazeux
 Aucun	 Précipitation immédiate
 Voie d'administration	 Perfusion intraveineuse
 Intramusculaire	 Bibliographie
 Dictionnaire	